William Fairey
Director/Board Member at MIRUM PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-03-30
Profile
William C.
Fairey is currently the Executive Chairman at Respira Therapeutics, Inc., an Independent Director at Aileron Therapeutics, Inc., an Independent Director at Ascendis Pharma A, and an Independent Director at Mirum Pharmaceuticals, Inc. He is also a Director at Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd.
and will be a Director at KalVista Pharmaceuticals, Inc. starting in 2024.
In his former positions, Mr. Fairey served as a Director at Lung Therapeutics LLC from 2021 to 2023, the Chief Operating Officer & Executive Vice President at ChemoCentryx, Inc. from 2018 to 2019, the Chief Commercial Officer & Executive VP at MyoKardia, Inc. from 2019 to 2020, and the President at Actelion Pharmaceuticals US, Inc. from 2013 to 2017.
He was also the President at Actelion Pharmaceuticals Canada, Inc. from 2003 to 2008 and the Regional Vice President-Australia Asia Pacific at Actelion Pharmaceuticals Ltd.
from 2008 to 2013.
Additionally, he held the position of Regional Vice President at Australia Asia Pacific Hotels Ltd.Mr. Fairey obtained an MBA from St. Mary's College of California in 1994 and completed his undergraduate studies at the University of Oregon in 1987.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-17 | 0 ( -.--% ) | - $ | 2024-03-30 | |
| 2023-04-16 | 0 ( -.--% ) | - $ | 2024-03-30 | |
| 2023-11-29 | 0 ( -.--% ) | - $ | 2024-03-30 | |
ASCENDIS PHARMA A/S
-.--% | 2023-12-30 | 0 ( -.--% ) | - $ | 2024-03-30 |
William Fairey active positions
| Companies | Position | Start |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Director/Board Member | 2021-08-18 |
| ASCENDIS PHARMA A/S | Director/Board Member | 2022-08-31 |
| AILERON THERAPEUTICS, INC. | Director/Board Member | 2023-10-30 |
| KALVISTA PHARMACEUTICALS, INC. | Director/Board Member | 2024-04-17 |
| Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd. | Director/Board Member | - |
Respira Therapeutics, Inc.
 Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM. | Chairman | 2021-12-31 |
Former positions of William Fairey
| Companies | Position | End |
|---|---|---|
Lung Therapeutics, Inc.
 Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Director/Board Member | 2023-10-30 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 2020-10-31 |
| CHEMOCENTRYX, INC. | Chief Operating Officer | 2019-01-17 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of William Fairey
| St. Mary's College of California | Masters Business Admin |
| University of Oregon | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| AILERON THERAPEUTICS, INC. | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| MIRUM PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 9 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Health Technology |
Actelion Pharmaceuticals US, Inc.
 Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a private company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | Health Technology |
Australia Asia Pacific Hotels Ltd.
 Australia Asia Pacific Hotels Ltd. Hotels/Resorts/Cruise linesConsumer Services Australia Asia Pacific Hotels Ltd. is an Australian private company located in Sydney. The firm operates hotels. | Consumer Services |
Respira Therapeutics, Inc.
Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM. | Health Technology |
| Actelion Pharmaceuticals Canada, Inc. | |
Actelion Pharmaceuticals Ltd.
 Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The private company is based in Allschwil, Switzerland. | Health Technology |
| Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd. |
- Stock Market
- Insiders
- William Fairey
